Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
David Berg, MD, MPH
Advertisement
Articles by David Berg, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
4
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
5